IDEAYA Biosciences (IDEAYA Biosciences) Current Ratio : 28.42 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. IDEAYA Biosciences's current ratio for the quarter that ended in Mar. 2024 was 28.42.

IDEAYA Biosciences has a current ratio of 28.42. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for IDEAYA Biosciences's Current Ratio or its related term are showing as below:

IDYA' s Current Ratio Range Over the Past 10 Years
Min: 4.5 Med: 12.02 Max: 28.42
Current: 28.42

During the past 7 years, IDEAYA Biosciences's highest Current Ratio was 28.42. The lowest was 4.50. And the median was 12.02.

IDYA's Current Ratio is ranked better than
95.3% of 1553 companies
in the Biotechnology industry
Industry Median: 3.79 vs IDYA: 28.42

IDEAYA Biosciences Current Ratio Historical Data

The historical data trend for IDEAYA Biosciences's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Current Ratio Chart

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Ratio

Get a 7-Day Free Trial

14.65

7.47

5.56

11.68

19.65

IDEAYA Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Ratio	Get a 7-Day Free Trial															11.53	19.80	19.37	19.65	28.42

Competitive Comparison of IDEAYA Biosciences's Current Ratio

For the Biotechnology subindustry, IDEAYA Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Current Ratio distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Current Ratio falls into.

IDEAYA Biosciences Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

IDEAYA Biosciences's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )	=	Total Current Assets (A: Dec. 2023 )	/	Total Current Liabilities (A: Dec. 2023 )
	=	532.632	/	27.101
	=	19.65

IDEAYA Biosciences's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )	=	Total Current Assets (Q: Mar. 2024 )	/	Total Current Liabilities (Q: Mar. 2024 )
	=	709.353	/	24.96
	=	28.42

IDEAYA Biosciences (NAS:IDYA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.

IDEAYA Biosciences Current Ratio Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Current Ratio

Comparable Companies

Traded in Other Exchanges

30J:Germany 30J:Germany

Address

7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Executives

Yujiro S Hata	director, officer: President and CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz	officer: See Remarks	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne	officer: VP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone	officer: SVP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre	officer: SVP, Chief Medical Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner	officer: SVP, Head of Biology	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman	10 percent owner, Former 10% holder	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p.	10 percent owner, Former 10% holder	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107